Global Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, and Devices), By Gender (Male, and Female), By Sales Channel, By Regional Outlook and Forecast, 2023 - 2030
The Global Androgenetic Alopecia Market size is expected to reach $4.6 billion by 2030, rising at a market growth of 8.1% CAGR during the forecast period.
Advancements in pharmaceutical R&D led to the discovery and development of innovative drugs for androgenetic alopecia. Therefore, the pharmaceuticals segment acquired $2,429.0 million revenue in 2022. New formulations and mechanisms of action expand the range of pharmaceutical options available to patients.
Cosmetic solutions are non-invasive and easy to use. Individuals can apply these products themselves, making them a convenient and user-friendly option for those who prefer non-surgical and non-pharmaceutical interventions. Thus, because of the increasing demand for cosmetic solutions, the market is anticipated to increase significantly.
Additionally, Androgenetic alopecia is more common in older age groups. The physiological changes associated with aging, such as hormonal shifts and reduced hair follicle function, contribute to a higher incidence of hair loss in the aging population. Hence, increasing number of senior citizens has been a pivotal factor in driving the growth of the market.
The market may experience disruptions in the supply chain, affecting the availability of pharmaceuticals, surgical instruments, and other related products. Delays in manufacturing and distribution can impact the delivery of treatments and interventions. Non-invasive and at-home solutions gained popularity. Thus, the COVID-19 pandemic had a moderate effect on the market.
However, High treatment costs may limit access to effective interventions, particularly for individuals with lower socioeconomic status or those without comprehensive health insurance coverage. This limited accessibility can result in a significant portion of the population being unable to afford advanced treatments. Thus, the high costs of some treatment options can slow down the growth of the market.
By Treatment Analysis
Based on treatment, the market is classified into pharmaceuticals and devices. The devices segment acquired a 3% revenue share in the market in 2022. The availability of devices for home use has expanded the reach of treatments. Home-use devices, such as laser caps and helmets, provide convenience for individuals seeking to address androgenetic alopecia in the comfort of their homes.
By Gender Analysis
By gender, the market is categorized into male and female. In 2022, the male segment acquired 70% revenue share in the market. Androgenetic alopecia is more prevalent in men than in women. As a result, men experiencing androgenetic alopecia may be more motivated to seek interventions to address hair loss, contributing to the uplift of the male segment in the market.
By Sales Channel Analysis
By sales channel, the market is segmented into prescriptions and OTC. The OTC segment recorded a remarkable 34% share in the market in 2022. The OTC segment offers a variety of products, including topical treatments, shampoos, supplements, and cosmetic solutions, providing consumers with diverse options to address their specific needs and preferences.
By End-use Analysis
On the basis of end-use, the market is divided into dermatology clinics and homecare settings. In 2022, the dermatology clinics segment dominated the market with 62.4% revenue share. These diagnostic tools help dermatologists accurately assess the severity and nature of androgenetic alopecia, guiding them in developing personalized treatment plans.
By Regional Analysis
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the 38.2% revenue share. In North America, individuals may start noticing hair loss in their 20s or 30s, increasing the risk.
List of Key Companies Profiled
- Cipla Limited
- Merck & Co., Inc.
- GlaxoSmithKline PLC (GSK)
- Sun Pharmaceuticals Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Aurobindo Pharma Limited
- Pfizer, Inc.
- Lutronic Co., Ltd.
- Viatris Inc.
- Eli Lilly and Company
Global Androgenetic Alopecia Market Report Segmentation
By Treatment
By Gender
By Sales Channel
By End-use
- Dermatology Clinics
- Homecare Settings
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1.Market Scope & Methodology
- 1.1Market Definition
- 1.2Objectives
- 1.3Market Scope
- 1.4Segmentation
- 1.4.1Global Androgenetic Alopecia Market, by Treatment
- 1.4.2Global Androgenetic Alopecia Market, by Gender
- 1.4.3Global Androgenetic Alopecia Market, by Sales Channel
- 1.4.4Global Androgenetic Alopecia Market, by End-use
- 1.4.5Global Androgenetic Alopecia Market, by Geography
- 1.5Methodology for the research
Chapter 2.Market at a Glance
Chapter 3.Market Overview
- 3.1Introduction
- 3.1.1Overview
- 3.1.1.1Market Composition and Scenario
- 3.2Key Factors Impacting the Market
- 3.2.1Market Drivers
- 3.2.2Market Restraints
- 3.2.3Market Opportunities
- 3.2.4Market Challenges
- 3.3Porter Five Forces Analysis
Chapter 4.Global Androgenetic Alopecia Market, By Treatment
- 4.1Global Pharmaceuticals Market, By Region
- 4.2Global Devices Market, By Region
Chapter 5.Global Androgenetic Alopecia Market, By Gender
- 5.1Global Male Market, By Region
- 5.2Global Female Market, By Region
Chapter 6.Global Androgenetic Alopecia Market, By Sales Channel
- 6.1Global Prescriptions Market, By Region
- 6.2Global OTC Market, By Region
Chapter 7.Global Androgenetic Alopecia Market, By End-use
- 7.1Global Dermatology Clinics Market, By Region
- 7.2Global Homecare Settings Market, By Region
Chapter 8.Global Androgenetic Alopecia Market, By Region
- 8.1North America Androgenetic Alopecia Market
- 8.1.1North America Androgenetic Alopecia Market, By Treatment
- 8.1.1.1North America Pharmaceuticals Market, By Country
- 8.1.1.2North America Devices Market, By Country
- 8.1.2North America Androgenetic Alopecia Market, By Gender
- 8.1.2.1North America Male Market, By Country
- 8.1.2.2North America Female Market, By Country
- 8.1.3North America Androgenetic Alopecia Market, By Sales Channel
- 8.1.3.1North America Prescriptions Market, By Country
- 8.1.3.2North America OTC Market, By Country
- 8.1.4North America Androgenetic Alopecia Market, By End-use
- 8.1.4.1North America Dermatology Clinics Market, By Country
- 8.1.4.2North America Homecare Settings Market, By Country
- 8.1.5North America Androgenetic Alopecia Market, By Country
- 8.1.5.1US Androgenetic Alopecia Market
- 8.1.5.1.1US Androgenetic Alopecia Market, By Treatment
- 8.1.5.1.2US Androgenetic Alopecia Market, By Gender
- 8.1.5.1.3US Androgenetic Alopecia Market, By Sales Channel
- 8.1.5.1.4US Androgenetic Alopecia Market, By End-use
- 8.1.5.2Canada Androgenetic Alopecia Market
- 8.1.5.2.1Canada Androgenetic Alopecia Market, By Treatment
- 8.1.5.2.2Canada Androgenetic Alopecia Market, By Gender
- 8.1.5.2.3Canada Androgenetic Alopecia Market, By Sales Channel
- 8.1.5.2.4Canada Androgenetic Alopecia Market, By End-use
- 8.1.5.3Mexico Androgenetic Alopecia Market
- 8.1.5.3.1Mexico Androgenetic Alopecia Market, By Treatment
- 8.1.5.3.2Mexico Androgenetic Alopecia Market, By Gender
- 8.1.5.3.3Mexico Androgenetic Alopecia Market, By Sales Channel
- 8.1.5.3.4Mexico Androgenetic Alopecia Market, By End-use
- 8.1.5.4Rest of North America Androgenetic Alopecia Market
- 8.1.5.4.1Rest of North America Androgenetic Alopecia Market, By Treatment
- 8.1.5.4.2Rest of North America Androgenetic Alopecia Market, By Gender
- 8.1.5.4.3Rest of North America Androgenetic Alopecia Market, By Sales Channel
- 8.1.5.4.4Rest of North America Androgenetic Alopecia Market, By End-use
- 8.2Europe Androgenetic Alopecia Market
- 8.2.1Europe Androgenetic Alopecia Market, By Treatment
- 8.2.1.1Europe Pharmaceuticals Market, By Country
- 8.2.1.2Europe Devices Market, By Country
- 8.2.2Europe Androgenetic Alopecia Market, By Gender
- 8.2.2.1Europe Male Market, By Country
- 8.2.2.2Europe Female Market, By Country
- 8.2.3Europe Androgenetic Alopecia Market, By Sales Channel
- 8.2.3.1Europe Prescriptions Market, By Country
- 8.2.3.2Europe OTC Market, By Country
- 8.2.4Europe Androgenetic Alopecia Market, By End-use
- 8.2.4.1Europe Dermatology Clinics Market, By Country
- 8.2.4.2Europe Homecare Settings Market, By Country
- 8.2.5Europe Androgenetic Alopecia Market, By Country
- 8.2.5.1Germany Androgenetic Alopecia Market
- 8.2.5.1.1Germany Androgenetic Alopecia Market, By Treatment
- 8.2.5.1.2Germany Androgenetic Alopecia Market, By Gender
- 8.2.5.1.3Germany Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.1.4Germany Androgenetic Alopecia Market, By End-use
- 8.2.5.2UK Androgenetic Alopecia Market
- 8.2.5.2.1UK Androgenetic Alopecia Market, By Treatment
- 8.2.5.2.2UK Androgenetic Alopecia Market, By Gender
- 8.2.5.2.3UK Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.2.4UK Androgenetic Alopecia Market, By End-use
- 8.2.5.3France Androgenetic Alopecia Market
- 8.2.5.3.1France Androgenetic Alopecia Market, By Treatment
- 8.2.5.3.2France Androgenetic Alopecia Market, By Gender
- 8.2.5.3.3France Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.3.4France Androgenetic Alopecia Market, By End-use
- 8.2.5.4Russia Androgenetic Alopecia Market
- 8.2.5.4.1Russia Androgenetic Alopecia Market, By Treatment
- 8.2.5.4.2Russia Androgenetic Alopecia Market, By Gender
- 8.2.5.4.3Russia Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.4.4Russia Androgenetic Alopecia Market, By End-use
- 8.2.5.5Spain Androgenetic Alopecia Market
- 8.2.5.5.1Spain Androgenetic Alopecia Market, By Treatment
- 8.2.5.5.2Spain Androgenetic Alopecia Market, By Gender
- 8.2.5.5.3Spain Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.5.4Spain Androgenetic Alopecia Market, By End-use
- 8.2.5.6Italy Androgenetic Alopecia Market
- 8.2.5.6.1Italy Androgenetic Alopecia Market, By Treatment
- 8.2.5.6.2Italy Androgenetic Alopecia Market, By Gender
- 8.2.5.6.3Italy Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.6.4Italy Androgenetic Alopecia Market, By End-use
- 8.2.5.7Rest of Europe Androgenetic Alopecia Market
- 8.2.5.7.1Rest of Europe Androgenetic Alopecia Market, By Treatment
- 8.2.5.7.2Rest of Europe Androgenetic Alopecia Market, By Gender
- 8.2.5.7.3Rest of Europe Androgenetic Alopecia Market, By Sales Channel
- 8.2.5.7.4Rest of Europe Androgenetic Alopecia Market, By End-use
- 8.3Asia Pacific Androgenetic Alopecia Market
- 8.3.1Asia Pacific Androgenetic Alopecia Market, By Treatment
- 8.3.1.1Asia Pacific Pharmaceuticals Market, By Country
- 8.3.1.2Asia Pacific Devices Market, By Country
- 8.3.2Asia Pacific Androgenetic Alopecia Market, By Gender
- 8.3.2.1Asia Pacific Male Market, By Country
- 8.3.2.2Asia Pacific Female Market, By Country
- 8.3.3Asia Pacific Androgenetic Alopecia Market, By Sales Channel
- 8.3.3.1Asia Pacific Prescriptions Market, By Country
- 8.3.3.2Asia Pacific OTC Market, By Country
- 8.3.4Asia Pacific Androgenetic Alopecia Market, By End-use
- 8.3.4.1Asia Pacific Dermatology Clinics Market, By Country
- 8.3.4.2Asia Pacific Homecare Settings Market, By Country
- 8.3.5Asia Pacific Androgenetic Alopecia Market, By Country
- 8.3.5.1China Androgenetic Alopecia Market
- 8.3.5.1.1China Androgenetic Alopecia Market, By Treatment
- 8.3.5.1.2China Androgenetic Alopecia Market, By Gender
- 8.3.5.1.3China Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.1.4China Androgenetic Alopecia Market, By End-use
- 8.3.5.2Japan Androgenetic Alopecia Market
- 8.3.5.2.1Japan Androgenetic Alopecia Market, By Treatment
- 8.3.5.2.2Japan Androgenetic Alopecia Market, By Gender
- 8.3.5.2.3Japan Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.2.4Japan Androgenetic Alopecia Market, By End-use
- 8.3.5.3India Androgenetic Alopecia Market
- 8.3.5.3.1India Androgenetic Alopecia Market, By Treatment
- 8.3.5.3.2India Androgenetic Alopecia Market, By Gender
- 8.3.5.3.3India Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.3.4India Androgenetic Alopecia Market, By End-use
- 8.3.5.4South Korea Androgenetic Alopecia Market
- 8.3.5.4.1South Korea Androgenetic Alopecia Market, By Treatment
- 8.3.5.4.2South Korea Androgenetic Alopecia Market, By Gender
- 8.3.5.4.3South Korea Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.4.4South Korea Androgenetic Alopecia Market, By End-use
- 8.3.5.5Australia Androgenetic Alopecia Market
- 8.3.5.5.1Australia Androgenetic Alopecia Market, By Treatment
- 8.3.5.5.2Australia Androgenetic Alopecia Market, By Gender
- 8.3.5.5.3Australia Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.5.4Australia Androgenetic Alopecia Market, By End-use
- 8.3.5.6Malaysia Androgenetic Alopecia Market
- 8.3.5.6.1Malaysia Androgenetic Alopecia Market, By Treatment
- 8.3.5.6.2Malaysia Androgenetic Alopecia Market, By Gender
- 8.3.5.6.3Malaysia Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.6.4Malaysia Androgenetic Alopecia Market, By End-use
- 8.3.5.7Rest of Asia Pacific Androgenetic Alopecia Market
- 8.3.5.7.1Rest of Asia Pacific Androgenetic Alopecia Market, By Treatment
- 8.3.5.7.2Rest of Asia Pacific Androgenetic Alopecia Market, By Gender
- 8.3.5.7.3Rest of Asia Pacific Androgenetic Alopecia Market, By Sales Channel
- 8.3.5.7.4Rest of Asia Pacific Androgenetic Alopecia Market, By End-use
- 8.4LAMEA Androgenetic Alopecia Market
- 8.4.1LAMEA Androgenetic Alopecia Market, By Treatment
- 8.4.1.1LAMEA Pharmaceuticals Market, By Country
- 8.4.1.2LAMEA Devices Market, By Country
- 8.4.2LAMEA Androgenetic Alopecia Market, By Gender
- 8.4.2.1LAMEA Male Market, By Country
- 8.4.2.2LAMEA Female Market, By Country
- 8.4.3LAMEA Androgenetic Alopecia Market, By Sales Channel
- 8.4.3.1LAMEA Prescriptions Market, By Country
- 8.4.3.2LAMEA OTC Market, By Country
- 8.4.4LAMEA Androgenetic Alopecia Market, By End-use
- 8.4.4.1LAMEA Dermatology Clinics Market, By Country
- 8.4.4.2LAMEA Homecare Settings Market, By Country
- 8.4.5LAMEA Androgenetic Alopecia Market, By Country
- 8.4.5.1Brazil Androgenetic Alopecia Market
- 8.4.5.1.1Brazil Androgenetic Alopecia Market, By Treatment
- 8.4.5.1.2Brazil Androgenetic Alopecia Market, By Gender
- 8.4.5.1.3Brazil Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.1.4Brazil Androgenetic Alopecia Market, By End-use
- 8.4.5.2Argentina Androgenetic Alopecia Market
- 8.4.5.2.1Argentina Androgenetic Alopecia Market, By Treatment
- 8.4.5.2.2Argentina Androgenetic Alopecia Market, By Gender
- 8.4.5.2.3Argentina Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.2.4Argentina Androgenetic Alopecia Market, By End-use
- 8.4.5.3UAE Androgenetic Alopecia Market
- 8.4.5.3.1UAE Androgenetic Alopecia Market, By Treatment
- 8.4.5.3.2UAE Androgenetic Alopecia Market, By Gender
- 8.4.5.3.3UAE Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.3.4UAE Androgenetic Alopecia Market, By End-use
- 8.4.5.4Saudi Arabia Androgenetic Alopecia Market
- 8.4.5.4.1Saudi Arabia Androgenetic Alopecia Market, By Treatment
- 8.4.5.4.2Saudi Arabia Androgenetic Alopecia Market, By Gender
- 8.4.5.4.3Saudi Arabia Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.4.4Saudi Arabia Androgenetic Alopecia Market, By End-use
- 8.4.5.5South Africa Androgenetic Alopecia Market
- 8.4.5.5.1South Africa Androgenetic Alopecia Market, By Treatment
- 8.4.5.5.2South Africa Androgenetic Alopecia Market, By Gender
- 8.4.5.5.3South Africa Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.5.4South Africa Androgenetic Alopecia Market, By End-use
- 8.4.5.6Nigeria Androgenetic Alopecia Market
- 8.4.5.6.1Nigeria Androgenetic Alopecia Market, By Treatment
- 8.4.5.6.2Nigeria Androgenetic Alopecia Market, By Gender
- 8.4.5.6.3Nigeria Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.6.4Nigeria Androgenetic Alopecia Market, By End-use
- 8.4.5.7Rest of LAMEA Androgenetic Alopecia Market
- 8.4.5.7.1Rest of LAMEA Androgenetic Alopecia Market, By Treatment
- 8.4.5.7.2Rest of LAMEA Androgenetic Alopecia Market, By Gender
- 8.4.5.7.3Rest of LAMEA Androgenetic Alopecia Market, By Sales Channel
- 8.4.5.7.4Rest of LAMEA Androgenetic Alopecia Market, By End-use
Chapter 9.Company Profiles
- 9.1Cipla Limited
- 9.1.1Company Overview
- 9.1.2Financial Analysis
- 9.1.3Segmental and Regional Analysis
- 9.1.4Research & Development Expense
- 9.1.5SWOT Analysis
- 9.2Merck & Co., Inc.
- 9.2.1Company Overview
- 9.2.2Financial Analysis
- 9.2.3Segmental and Regional Analysis
- 9.2.4Research & Development Expenses
- 9.2.5SWOT Analysis
- 9.3GlaxoSmithKline PLC (GSK)
- 9.3.1Company Overview
- 9.3.2Financial Analysis
- 9.3.3Regional Analysis
- 9.3.4Research & Development Expense
- 9.3.5SWOT Analysis
- 9.4Sun Pharmaceuticals Industries Ltd.
- 9.4.1Company Overview
- 9.4.2Financial Analysis
- 9.4.3Regional Analysis
- 9.4.4Research & Development Expenses
- 9.4.5SWOT Analysis
- 9.5Dr. Reddy's Laboratories Ltd.
- 9.5.1Company Overview
- 9.5.2Financial Analysis
- 9.5.3Segmental and Regional Analysis
- 9.5.4Research & Development Expense
- 9.5.5Recent strategies and developments:
- 9.5.5.1Product Launches and Product Expansions:
- 9.5.6SWOT Analysis
- 9.6Aurobindo Pharma Limited
- 9.6.1Company Overview
- 9.6.2Financial Analysis
- 9.6.3Regional Analysis
- 9.6.4Research & Development Expense
- 9.6.5SWOT Analysis
- 9.7Pfizer, Inc.
- 9.7.1Company Overview
- 9.7.2Financial Analysis
- 9.7.3Regional & Segmental Analysis
- 9.7.4Research & Development Expense
- 9.7.5Recent strategies and developments:
- 9.7.5.1Trails and Approvals:
- 9.7.6SWOT Analysis
- 9.8Lutronic Co., Ltd.
- 9.8.1Company Overview
- 9.8.2Financial Analysis
- 9.8.3Regional Analysis
- 9.8.4Research & Development Expenses
- 9.8.5SWOT Analysis
- 9.9Viatris, Inc.
- 9.9.1Company Overview
- 9.9.2Financial Analysis
- 9.9.3Segmental Analysis
- 9.9.4Research & Development Expense
- 9.9.5SWOT Analysis
- 9.10.Eli Lilly And Company
- 9.10.1Company Overview
- 9.10.2Financial Analysis
- 9.10.3Regional Analysis
- 9.10.4Research & Development Expenses
- 9.10.5SWOT Analysis
Chapter 10.Winning Imperative of Androgenetic Alopecia Market
